Position of the Transparency Council – Ebglyss (Lebrikizumab)
At its meeting on 24 February 2025, the Transparency Council adopted position No. 21/2025 on the evaluation of the drug Ebglyss (Lebrikizumab) under the drug program B.124. “Treatment of patients with atopic dermatitis (ICD-10: L20)”
Publication of the position >>